Table 2.
Main characteristics of the studies included.
| References | Study design | Study period | Study region | ICI treatment | Cancer Type | Sample size | Age (years) | Gender (male/female) | Outcome | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
| Chang et al.26 | R | 01/2017–10/2020 | China | Camrelizumab, Sintilimab, Toripalimab | EC | 69 | 60 (44–78)a | 67/2 | OS (M), PFS (M), ORR (U), DCR (U) | 7 |
| Chen et al.24 | R | 08/2016–12/2020 | China | ICIs | GC | 89 | – | – | OS (U), PFS (U) | 7 |
| Chen et al.27 | S | 06/2019–09/2020 | China | Sintilimab | HCC | 20 | 56 (41–70)a | 18/2 | PFS (U) | 6 |
| Ohba et al.23 | R | 02/2017–01/2018 | Japan | Pembrolizumab | NSCLC | 32 | 65 (44–85)a | 29/3 | OS (M), PFS (M), ORR (U), DCR (U) | 7 |
| Sakai et al.28 | R | 04/2017–06/2022 | Japan | Nivolumab, Pembrolizumab | HNSCC | 102 | 70 (47–87)a | 93/9 | OS (U), PFS (U), ORR (U), DCR (U) | 8 |
| Takemura et al.29 | R | 2016–2019 | Japan | Nivolumab | RCC | 60 | 68 (60–76)b | 45/15 | OS (U), PFS (U) | 7 |
| Zhang et al.30 | R | 2019–2021 | China | Camrelizumab, Toripalimab, Pembrolizumab | ESCC | 243 | – | – | OS (U), PFS (U) | 8 |
| Zhao et al.31 | R | 01/2018–04/2021 | China | Camrelizuma | ESCC | 48 | 65c | 32/16 | OS (U), PFS (M), ORR (U) | 7 |
aMedians (ranges).
bMedians (interquartile range).
cMedians.
R retrospective study, S single-arm study, M multivariate analysis, U univariate analysis, ICIs immune checkpoint inhibitors, EC esophageal cancer, GC gastric cancer, HCC hepatocellular carcinoma, NSCLC non-small cell lung cancer, HNSCC squamous cell carcinoma of head and neck, RCC renal cell carcinoma, ESCC esophageal squamous cell carcinoma, OS overall survival, PFS progression-free survival, ORR objective response rate, DCR disease control rate.